HN011 A Randomized Phase II Study of Nivolumab Versus Nivolumab and Relatlimab as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine- Nivolumab for Patients with Epstein- Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma



Mary Beth Wilwerding, RN Admin@NEcancertrials.com



Available at Nebraska Methodist Estabrook Cancer Center

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*

Email*

Phone*

Message*